Marqibo Interactions
There are 437 drugs known to interact with Marqibo (vincristine liposome), along with 6 disease interactions. Of the total drug interactions, 75 are major, 345 are moderate, and 17 are minor.
- View all 437 medications that may interact with Marqibo
- View Marqibo disease interactions (6)
Most frequently checked interactions
View interaction reports for Marqibo (vincristine liposome) and the medicines listed below.
- Adriamycin RDF (doxorubicin)
- Advate (antihemophilic factor)
- Adzenys XR-ODT (amphetamine)
- Alimta (pemetrexed)
- Alphanate (antihemophilic factor/von willebrand factor)
- amlodipine / hydrochlorothiazide / olmesartan
- Bactrim DS (sulfamethoxazole / trimethoprim)
- Baraclude (entecavir)
- Capastat (capreomycin)
- Celestone Soluspan (betamethasone)
- Cipro I.V. (ciprofloxacin)
- Copiktra (duvelisib)
- Cotempla XR-ODT (methylphenidate)
- Crixivan (indinavir)
- Cytoxan (cyclophosphamide)
- Decadron (dexamethasone)
- Duopa (carbidopa / levodopa)
- Enbrel (etanercept)
- Epivir-HBV (lamivudine)
- Etopophos (etoposide)
- Feiba (anti-inhibitor coagulant complex)
- Gamifant (emapalumab)
- Gammagard S/D (immune globulin intravenous)
- gemfibrozil
- glimepiride / rosiglitazone
- Hemofil-M (antihemophilic factor)
- HepaGam B (hepatitis b immune globulin)
- Humate-P (antihemophilic factor/von willebrand factor)
- Humatin (paromomycin)
- Humira (adalimumab)
Marqibo disease interactions
There are 6 disease interactions with Marqibo (vincristine liposome) which include:
- pulmonary dysfunction
- neurologic dysfunction
- constipation
- hepatic dysfunction
- infections
- myelosuppression
More about Marqibo (vincristine liposome)
- Marqibo consumer information
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: mitotic inhibitors
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.